newsit

“Get Ready to Wave Goodbye to Lymphoma: Merck’s Exciting Phase 3 Trial for Zilovertamab Vedotin is Here!”

Merck Announces Phase 3 Clinical Trial for DLBCL Treatment A New Hope for Patients with Diffuse Large B-cell Lymphoma Rahway, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of waveLINE-010, a pivotal Phase 3 clinical trial evaluating zilovertamab vedotin in combination with rituximab plus cyclophosphamide,…

Read More

“Rithm Capital Corp. Unveils Impressive Fourth Quarter and Full Year 2024 Results: A Look into the Future of Success”

Rithm Capital Corp. Reports Strong Financial Results for Q4 and Full Year 2024 Fourth Quarter 2024 Financial Highlights Rithm Capital Corp. (NYSE: RITM) has announced its financial results for the fourth quarter ended December 31, 2024. The company reported GAAP net income of $263.2 million, equivalent to $0.50 per diluted common share. Earnings available for…

Read More

“Siemens Healthineers: Welcoming a Smaller Share from Siemens by 2025!”

Siemens Healthineers Looks Towards a Bright Future A Positive Outlook for the Medical-Technology Company Siemens Healthineers’ CEO recently shared that the company has a “very positive” view on considerations by parent Siemens to reduce its stake. This news comes as a reassurance to employees, investors, and customers alike, signaling a promising future for the renowned…

Read More

“Reflecting on Success: Hilton’s Fourth Quarter and Record Full Year Results”

Hilton Worldwide Holdings Inc. Reports Strong Fourth Quarter and Full Year 2024 Results Key Highlights: Diluted EPS Exceeds Guidance Hilton Worldwide Holdings Inc. (“Hilton”) has announced its fourth quarter and full year 2024 results, with diluted earnings per share (EPS) surpassing the high end of guidance. For the fourth quarter, diluted EPS was $2.06, while…

Read More